Evidence map›Paper›PMID 37664638›Full record

ArticleiScience2023

A personalized stepwise dynamic predictive algorithm of the time to first treatment in chronic lymphocytic leukemia.

Theodoros Moysiadis, Dimitris Koparanis, Konstantinos Liapis, Maria Ganopoulou, George Vrachiolias, Ioannis Katakis, Chronis Moyssiadis, Ioannis S Vizirianakis, Lefteris Angelis, Konstantinos Fokianos and 1 more

Abstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Theodoros MoysiadisDepartment of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace Medical School, 68100 Alexandroupolis, Greece.
Dimitris KoparanisDepartment of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace Medical School, 68100 Alexandroupolis, Greece.
Konstantinos LiapisDepartment of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace Medical School, 68100 Alexandroupolis, Greece.
Maria GanopoulouSchool of Informatics, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
George VrachioliasDepartment of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace Medical School, 68100 Alexandroupolis, Greece.
Ioannis KatakisDepartment of Computer Science, School of Sciences and Engineering, University of Nicosia, 2417 Nicosia, Cyprus.
Chronis MoyssiadisSchool of Mathematics, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Ioannis S VizirianakisSchool of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Lefteris AngelisSchool of Informatics, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Konstantinos FokianosDepartment of Mathematics & Statistics, University of Cyprus, 1678 Nicosia, Cyprus.
Ioannis KotsianidisDepartment of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace Medical School, 68100 Alexandroupolis, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized prediction is ideal in chronic lymphocytic leukemia (CLL). Although refined models have been developed, stratifying patients in risk groups, it is required to accommodate time-dependent information of patients, to address the clinical heterogeneity observed within these groups. In this direction, this study proposes a personalized stepwise dynamic predictive algorithm (PSDPA) for the time-to-first-treatment of the individual patient. The PSDPA introduces a personalized Score, reflecting the evolution in the patient's follow-up, employed to develop a reference pool of patients. Score evolution's similarity is used to predict, at a selected time point, the time-to-first-treatment for a new patient. Additional patient's biological information may be utilized. The algorithm was applied to 20 CLL patients, indicating that stricter assessment criteria for the Score evolution's similarity, and biological similarity exploitation, may improve prediction. The PSDPA capitalizes on both the follow-up and the biological background of the individual patient, dynamically promoting personalized prediction in CLL.

Indexed as

Cancer systems biologyComputational bioinformaticsHealth sciencesMathematical biosciences

Identifiers

PMID37664638
PMCPMC10470317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.